Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Joint venture for development of MPS I treatment now a reality

Sep. 16, 1998

Novel glucagon receptor antagonist with potential in treating type I/type II diabetes

Sep. 15, 1998

Amgen describes preparation and use of KGF proteins

Sep. 15, 1998

Melanotan II effective as a treatment for psychogenic erectile dysfunction

Sep. 15, 1998

Development of MGDF discontinued at Amgen

Sep. 14, 1998

Nateglinide preclinical and clinical data featured at diabetes meeting

Sep. 14, 1998

Heart valve abnormalities a problem among appetite suppressant-treated obese patients

Sep. 14, 1998

U.K. filing announced for MED treatment option

Sep. 11, 1998

Clinical studies on Hoe-901 reported at European diabetes meeting

Sep. 11, 1998

Amgen initiates clinical trials of novel bone protective agent

Sep. 11, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...